An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. The firm is current investing from its newest US$100 million and RMB 1 billion funds closed in 2016. Typical equity allocations range from US$2-6 million in an early stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, US, and EU.
The firm currently focuses on medical devices and IVD tools in late clinical development or early commercial stage with high entry battier. The firm focuses on diseases with large market potential such as oncology and cardiovascular conditions.
The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angle; however this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of joint venture and strategic partnership in the country.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Leave a Reply